Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The downward momentum from last week's Q3 update continues.

Why Zomedica Stock Is Sinking This Week

It's a risky play no doubt, but ZOM stock stands to get out of its current rut as a key temporary issue subsides. The post Zomedica Is Languishing Today, but Keep an Eye on This Risky Play appeared first on InvestorPlace.

Zomedica Is Languishing Today, but Keep an Eye on This Risky Play

Alzamend Neuro

NuZee, Inc.

Check these penny stocks out for your watchlist this week The post Are These Penny Stocks on Your Watchlist This Week? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are These Penny Stocks on Your Watchlist This Week?

ANN ARBOR, MI / ACCESSWIRE / November 12, 2021 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company"), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financial results for the three and nine months ended September 30, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America ("U.S. GAAP").

Zomedica Announces Third Quarter 2021 Financial Results

Vinco Ventures

Grom Social Enterprises

Globalstar

Kaival Brands Innovations Group

Senseonics Holdings

Super League Gaming Inc

While meme trends are on the wane, these seven penny stocks still stand to make turbocharged moves higher in the short-term. The post 7 Penny Stocks That Could Have an Explosive Year-End appeared first on InvestorPlace.

7 Penny Stocks That Could Have an Explosive Year-End

Speculative pet stocks TDH Holdings and Zomedica are jumping higher in morning trading but investors should be skeptical of the moves. The post Pet Stocks Alert: What Is Going on With PETZ and ZOM Stocks Today?

Pet Stocks Alert: What Is Going on With PETZ and ZOM Stocks Today?

Digital World Acquisition Corp

Sometimes the safest decision is to hold cash and wait for an opportunity.

2 Risky Stocks I Wouldn't Buy With Free Money

ZOM stock had its best days in early 2021, but now its weak financial performance fully justifies its price weakness. The post Stay Away From Zomedica for These 3 Key Reasons appeared first on InvestorPlace.

Stay Away From Zomedica for These 3 Key Reasons

Zomedica's acquisition is precisely what was needed to get ZOM stock out of its lethargy. Long-term, it could be a game-changer.

Zomedica Management Finally Delivers Some Good News

While a C-suite scenery change might be good for Zomedica, the shift may not provide a similar outcome for ZOM stock. The post Zomedica Stock Will Need More Than a Change in Management to Bounce Back appeared first on InvestorPlace.

Zomedica Stock Will Need More Than a Change in Management to Bounce Back

A turnaround in ZOM stock may happen sooner rather than later as Zomedica undergoes an executive-level change and builds out its business. The post New CEO and Acquisition Could Breathe New Life Into Zomedica appeared first on InvestorPlace.

New CEO and Acquisition Could Breathe New Life Into Zomedica

ZOM stock can be a pet care industry leader, but it needs to make significant improvements before becoming a solid long-term play. The post Zomedica Has Potential, but It's Far Too Expensive for Now appeared first on InvestorPlace.

Zomedica Has Potential, but It's Far Too Expensive for Now

Cautious investors may want to hold off, as no matter what direction it goes (higher or lower), it'll do so in a big way. But if you can stomach the risk, and have patience to wait out its current troubles, ZOM stock may be an opportunity.

The Challenges for Zomedica Continue, But It Still Has Huge Potential

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) increased by over 2% pre-market today. This is why it happened.

ZOM Stock: Why It Increased Today

ANN ARBOR, Mich., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, today announced that Larry Heaton has been appointed President effective October 1, 2021. Mr. Heaton will assume the role of Chief Executive Officer upon the retirement of current Chief Executive Officer Robert Cohen on October 31, 2021. Following his retirement, Mr. Cohen will remain on the Board of Directors of Zomedica.

Zomedica Appoints Larry Heaton as President and Announces CEO Succession Plan

Investors applauded the company's move to diversify its business.

Here's Why Zomedica Stock Popped Today

Meten Holding Group Ltd.

Progenity

These penny stocks are pushing up right now, are they on your watchlist? The post Investing in Penny Stocks?

Investing in Penny Stocks? Here's 3 That Retail Traders Are Watching

Aeterna Zentaris

A few hot penny stocks are seeing major movement on Friday as shares ride higher and we've got all the details traders need. The post 3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today appeared first on InvestorPlace.

3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today

ZOM stock is up big today on news of a big merger. The company is acquiring proven vet tech outfit PulseVet in an all-cash deal.

ZOM Stock: There's a $71 Million Reason Zomedica Is Gaining Today

Zomedica Corp (AMEX:ZOM) is trading significantly higher Friday after the company announced the purchase of Pulse Veterinary Technologies for $70.9 million in cash and stock. Pulse Veterinary Technologies uses electro-hydraulic shock wave technology for the treatment of a wide variety of conditions in veterinary patients.

Why Zomedica Shares Are Soaring Today

Zomedica Corp (NYSE:ZOM) has acquired the Pulse Veterinary Technologies businesses for $70.9 million in a cash and stock transaction. Pulse Veterinary Technologies (PulseVet) provides electro-hydraulic shock wave technology to treat a wide variety of conditions in veterinary patients.

Zomedica Stock Soars After $71M Pulse Veterinary Acquisition

ANN ARBOR, Mich., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, today announced that it had acquired the Pulse Veterinary Technologies businesses for $70.9 million in an all-cash, stock transaction.

Zomedica Acquires PulseVet

The only word out of Zomedica in September was its announcement of a new director. That's not the news ZOM stock needs right now.

With the Crickets Chirping at Zomedica HQ, Why Buy the Stock?

AMC Entertainment

Aterian

DoorDash

Royal Caribbean Cruises

Teladoc

Uber

It's the time of the year when it's just as important to identify which stocks to sell as it is to know which ones to buy. The post 7 Stocks to Sell Now to Lock in Profits While You Still Can appeared first on InvestorPlace.

7 Stocks to Sell Now to Lock in Profits While You Still Can

At one point, investors loved Zomedica. But until its plans come to fruition, ZOM stock doesn't look like much of a deal.

News for Zomedica Stock (ZOM)